JP2006507270A5 - - Google Patents

Download PDF

Info

Publication number
JP2006507270A5
JP2006507270A5 JP2004545186A JP2004545186A JP2006507270A5 JP 2006507270 A5 JP2006507270 A5 JP 2006507270A5 JP 2004545186 A JP2004545186 A JP 2004545186A JP 2004545186 A JP2004545186 A JP 2004545186A JP 2006507270 A5 JP2006507270 A5 JP 2006507270A5
Authority
JP
Japan
Prior art keywords
composition
beta
gastrointestinal
infection
microbial infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004545186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006507270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/003455 external-priority patent/WO2004035008A2/en
Publication of JP2006507270A publication Critical patent/JP2006507270A/ja
Publication of JP2006507270A5 publication Critical patent/JP2006507270A5/ja
Pending legal-status Critical Current

Links

JP2004545186A 2002-02-06 2003-02-06 感染症および他の疾患の治療 Pending JP2006507270A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35425002P 2002-02-06 2002-02-06
US42103802P 2002-10-25 2002-10-25
PCT/US2003/003455 WO2004035008A2 (en) 2002-02-06 2003-02-06 Treatment of infections and other disorders

Publications (2)

Publication Number Publication Date
JP2006507270A JP2006507270A (ja) 2006-03-02
JP2006507270A5 true JP2006507270A5 (enExample) 2006-04-13

Family

ID=32109894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004545186A Pending JP2006507270A (ja) 2002-02-06 2003-02-06 感染症および他の疾患の治療

Country Status (6)

Country Link
US (2) US20060089310A1 (enExample)
EP (2) EP2266595A3 (enExample)
JP (1) JP2006507270A (enExample)
AU (1) AU2003296875B2 (enExample)
CA (1) CA2475053A1 (enExample)
WO (1) WO2004035008A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076254A2 (en) * 2005-01-11 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing respiratory microbial infection of respiratory tissue
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
AU2011218617B2 (en) * 2004-05-12 2014-09-04 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
CA2607686C (en) 2004-05-12 2014-11-04 Thomas P. Stossel Use of gelsolin to treat infections
KR100716119B1 (ko) * 2005-10-24 2007-05-10 (주)케어젠 모발 성장을 촉진하는 펩티드 및 이를 이용한 화장품
AU2007227613A1 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP2002258B1 (en) 2006-03-15 2017-09-27 The Brigham and Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
US8399412B2 (en) 2006-10-06 2013-03-19 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions
KR20100057050A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 데슬로렐린 및 마스토파란의 용도
US20100210540A1 (en) * 2007-09-11 2010-08-19 Dorian Bevec Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
JP5778425B2 (ja) 2008-01-25 2015-09-16 ザ ジェネラル ホスピタル コーポレイション 腎不全におけるゲルソリンの診断的および治療的使用
MX2010010177A (es) * 2008-03-17 2012-08-23 Regenerx Biopharmaceuticals Fragmentos de beta timosina mejorada.
US8609604B2 (en) 2009-12-28 2013-12-17 N.V. Perricone Llc Methods of improving the appearance of aging skin
US8580742B2 (en) 2010-03-05 2013-11-12 N.V. Perricone Llc Topical glutathione formulations for menopausal skin
US20110160144A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Formulations
BR112013000923A2 (pt) * 2010-07-14 2016-05-17 Adistem Ltd método de tratamento de hiv ou aids
CN103724422B (zh) * 2014-01-13 2015-10-21 哈尔滨吉象隆生物技术有限公司 一种裂解胸腺素β4的方法
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
CA2156735A1 (en) * 1993-02-22 1994-09-01 Ulrich-Christoph Von Arnim Pharmaceutical compositions for the treatment of inflammatory or immunological diseases and a method for the treatment of said diseases
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
PT1100529E (pt) * 1998-07-30 2005-10-31 Us Gov Health & Human Serv A timosina beta 4 promove a preparacao de feridas
AU4461300A (en) * 1999-04-14 2000-11-14 Southco, Inc. Crescent hinge
AU2002336408B2 (en) * 2001-08-29 2006-12-21 Regenerx Biopharmaceuticals, Inc. Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
KR102632066B1 (ko) 2015-07-30 2024-02-02 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 장치의 제작 방법, 발광 장치, 모듈, 및 전자 기기

Similar Documents

Publication Publication Date Title
JP2006507270A5 (enExample)
Langoth et al. Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system
ES2565564T3 (es) Una composición que comprende un antibiótico y un dispersante
JP5969457B2 (ja) 化合物およびそれらの使用
DK1739178T3 (da) Levering af trekløverpeptider
US20030171281A1 (en) Antimicrobial cationic peptides and formulations thereof
EP1718325B1 (en) Treatment of bacterial infections
AU2003296875A1 (en) Treatment of infections and other disorders
CA2513567A1 (en) Cop 1 for treatment of inflammatory bowel diseases
EP1421108A2 (en) Antimicrobial and anti-inflammatory peptides
JP6157514B2 (ja) 抗菌性ペプチド
US20040152624A1 (en) Oral lactoferrin in the treatment of sepsis
JP2018531880A5 (enExample)
JP2009500045A5 (enExample)
JP2004534084A5 (enExample)
JP4554150B2 (ja) 薬剤耐性菌による感染症治療剤
JP6018614B2 (ja) アンギオテンシンi転換酵素抑制と血圧低下に用いる短鎖活性ペプチド
CN101247721B (zh) 包括酪蛋白衍生肽的药物组合物及其使用方法
CN101342187B (zh) 一种治疗痢疾的药物组合物
CN101415725B (zh) 具有生物活性的肽化合物、其制备及其应用
CN103384523B (zh) 硝呋太尔在治疗由梭菌属物种所引起的感染中的用途
ITMI20091122A1 (it) Formulazioni farmaceutiche per uso intravaginale nella prevenzione e terapia delle vulvo vaginiti e nel ripristino della fisiologia vaginale
JP2009502810A5 (enExample)
US20220133699A1 (en) Antibacterial Compositions
CN1299698C (zh) 圆口纲动物唾液腺分泌物在制药中的应用